Citizens JMP analyst Jonathan Wolleben has increased the price target for DBV Technologies (DBVT, Financial) from $10 to $15, maintaining an Outperform rating on the stock. According to a research note, DBV Technologies has secured $128 million in pro forma cash, providing the company with financial flexibility until the second quarter of 2026. This outlook does not yet account for a potential $180 million influx from warrants, contingent upon the success of the Phase 3 VITESSE trial anticipated in the fourth quarter of 2025.
The analyst highlights several positive strides DBV has made this year. Among these is the promising three-year data revealing that Viaskin Peanut's safety and effectiveness in children aged 1-3 shows improvement over time. The firm suggests that DBV needs to fortify its financial standing, implying that recent achievements have bolstered investor confidence.
